Intellia Therapeutics, Inc. (LON:0JBU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.48B +133.1% |
| Revenue (ttm) | 50.05M +45.0% |
| Net Income | -298.83M |
| EPS | -2.67 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,351 |
| Average Volume | 42,951 |
| Open | 14.17 |
| Previous Close | 13.91 |
| Day's Range | 13.76 - 14.31 |
| 52-Week Range | 6.83 - 28.33 |
| Beta | 1.93 |
| RSI | 52.04 |
| Earnings Date | May 14, 2026 |
About Intellia Therapeutics
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial numbers in USD Financial StatementsNews
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
Bernstein raised the firm’s price target on Intellia Therapeutics (NTLA) to $17 from $13 and keeps a Market Perform rating on the shares. Biotech has had a strong start to…
Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent…
Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Phase III HAELO study showed 87% attack rate reduction and 62% of patients attack free, surpassing competitors. Commercial launch of lonvo-z is targeted for next year, with strong payer interest and robust financial position supporting operations into 2028.
Intellia Therapeutics price target lowered to $19 from $20 at BofA
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated operating expense trends and share…
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $49 from $58 and keeps a Buy rating on the shares. The firm said its 1Q26 report was largely…
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
Reports Q1 revenue $15.05M, consensus $13.81M. “It has been a remarkable start to 2026 for Intellia,” said John Leonard, Intellia President and Chief Executive Officer. “With lonvo-z, we achieved a…
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
20:06 EDT Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today
23:21 EDT Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics (NTLA) today
Unusually active option classes on open April 29th
Unusual total active option classes on open include: Intellia Therapeutics (NTLA), Teva (TEVA), FuelCell (FCEL), iShares 20 Year Treasury Bond ETF (TLT), BigBearai Holdings (BBAI), Qualcomm (QCOM), Jo...
Intellia Therapeutics 16.7M share Secondary priced at $10.75
The deal size was increased to $180M in common stock from $150M in common stock. Jefferies, Goldman Sachs and Citi acted as joint book running managers for the offering. Published…
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today
20:06 EDT Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics (NTLA) today
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio move on Monday, April 27, 2026, as shown in ARK’s daily fund disclosures. The firm continued to reduce its position in the ...
Intellia Therapeutics price target raised to $13 from $7 at Baird
Baird raised the firm’s price target on Intellia Therapeutics (NTLA) to $13 from $7 and keeps a Neutral rating on the shares. The firm updated its model following positive pivotal…
Intellia Therapeutics price target raised to $58 from $48 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Intellia Therapeutics (NTLA) to $58 from $48 and keeps a Buy rating on the shares. The firm updated its model…
Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $8 and keeps a Sell rating on the shares.
Intellia Therapeutics price target raised to $30 from $28 at Citizens
Citizens raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $28 and keeps an Outperform rating on the shares. Intellia’s Phase 3 HAELO outcome are positive for…
Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today
20:09 EDT Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics announces $150M common stock offering
Intellia Therapeutics (NTLA) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the proposed offering are to…
Intellia Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics price target raised to $30 from $27 at Chardan
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $27 and keeps a Buy rating on the shares. The company this morning reported positive results from…
Intellia Therapeutics Transcript: Study result
The phase III HAELO trial showed that a single dose of lonvo-z, an in vivo CRISPR-based gene-editing therapy, led to an 87% reduction in HAE attack rates and 62% of patients being attack- and therapy-free at six months, with a favorable safety profile. Early crossover data suggest further improvements over time. Additional long-term data and subgroup analyses will be presented at EAACI.